Sildenafil Tablet, Film Coated
Product Images NDC 71205-509

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Sildenafil (NDC 71205-509). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 6: Kaplan-meier Plot Of Mortality By Sildenafil Dose (Image 1)

FDA Label Image

Sildenafil Citrate Structural Formula (Image 2)

FDA Label Image

\\client\x$\products\sildenafil Tabs Usp, 20 mg (078380)\submissions\2016-11-03 (piramal) (AJK\Working\Inserts\Image files\sildenafil-f7new.jpg)

\\client\x$\products\sildenafil Tabs Usp, 20 mg (078380)\submissions\2016-11-03 (piramal) (AJK\Working\Inserts\Image files\sildenafil-f7new.jpg)
This appears to be a table listing different drugs including Atorvastatin, Azithromycin, Bosentan, Cimetidine, Erythromycin, Maalox, Oral Contraceptives, Ritonavir, and Saquinavir, along with their effects on AUC and Cmax. The table also includes recommendations for fold change and 90% CI based on the drug interaction. The text mentions no dose adjustment required for most drugs, except for co-administration of sildenafil with bosentan, which is not recommended. There is also a note that sildenafil added to bosentan therapy has no benefit on exercise capacity.*
FDA Label Image

Figure 8: Effects Of Sildenafil On Other Drugs (Image 4)

FDA Label Image

Figure 9. Change From Baseline In 6-minute Walk Distance (meters) At Weeks 4, 8, And 12 In Study 1: Mean (95% Confidence Interval) (Image 5)

FDA Label Image

Figure 10. Placebo-corrected Change From Baseline In 6-minute Walk Distance (meters) At Week 12 By Study Subpopulation In Study 1: Mean (95% Confidence Interval) (Image 6)

Figure 10. Placebo-corrected Change From Baseline In 6-minute Walk Distance (meters) At Week 12 By Study Subpopulation In Study 1: Mean (95% Confidence Interval) (Image 6)
This appears to be a table showing results from a clinical trial involving patients with different types of pulmonary arterial hypertension (PAH) who were given either a placebo or sildenafil (at a dose of 20 mg three times a day). The table shows various parameters that were measured in the patients, such as their functional capacity, therapeutic class, gender, age, mean pulmonary artery pressure, and pulmonary vascular resistance index. The last row of the table shows the change in the 6-minute walk distance for the placebo group compared to the sildenafil group.*
FDA Label Image

Figure 11. Kaplan-meier Plot Of Time (in Days) To Clinical Worsening Of Pah In Study 2 (Image 7)

FDA Label Image

Figure 12. Mean Change From Baseline In Six Minute Walk (meters) By Visit To Week 12 – Itt Population Sildenafil Protocol A1481244 (Image 8)

FDA Label Image

71205-509-90 (Image 9)

71205-509-90 (Image 9)
This is a description of a medication called Sildenafil 20mg that comes in a bottle of 90 tablets. Each tablet contains sildenafil citrate, USP equivalent to 20mg sildenafil. The tablets are white and film-coated, unscored, round biconvex and debossed with “TEVA" on one side of the tablet and “5517" on the other side. The product ID is S050990 and it is made by Teva Pharmaceuticals USA, Inc. This medication should be stored at 20°-25°C (68°-77°F) and kept out of reach of children. The medication was relabeled by Proficent Rx LP, Thousand Oaks, CA 91320. There are also some codes like NDC 71205-509-90 and GTIN: 0371205509903 mentioned but there is not enough information to determine what they are for.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.